Zonampanel is a neuroprotective AMPA receptor antagonist that is currently under examination as a potential treatment for cerebral ischemia/stroke. In animal models of stroke, zonampanel improves neurological deficits but does not exacerbate intracerebral hemorrhage.
| Cas No. | 210245-80-0 |
|---|---|
| Purity | ≥97% |
| Formula | C13H9N5O6 |
| Formula Wt. | 331.24 |
| Chemical Name | (2,3-Dioxo-7-(1H-imidazol-1-yl)-6-nitro-1,2,3,4- tetrahydro-1-quinoxalinyl)acetic acid monohydrate |
| IUPAC Name | 2-(7-imidazol-1-yl-6-nitro-2,3-dioxo-4H-quinoxalin-1-yl)acetic acid |
| Synonym | YM872, HY-15072 |
| Solubility | Solubility in buffer pH 7 is ≥80mg/mL. |
| Appearance | Yelowish to Tan Powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | Z5852 Info Sheet PDF |
|---|
Ferro JM, Dávalos A. Other neuroprotective therapies on trial in acute stroke. Cerebrovasc Dis. 2006;21 Suppl 2:127-30. PMID: 16651823.
Terai K, Suzuki M, Sasamata M, et al. Effect of AMPA receptor antagonist YM872 on cerebral hematoma size and neurological recovery in the intracerebral hemorrhage rat model. Eur J Pharmacol. 2003 Apr 25;467(1-3):95-101. PMID: 12706461.
